HC Wainwright Issues Pessimistic Outlook for GLSI Earnings

Greenwich LifeSciences, Inc. (NASDAQ:GLSI – Free Report) – Research analysts at HC Wainwright decreased their FY2026 earnings per share estimates for Greenwich LifeSciences in a research report issued on Wednesday, November 18th. HC Wainwright analyst Y. Chen now expects that the company will post earnings of ($1.46) per share for the year, down from their previous estimate of ($1.29). HC Wainwright currently has a “Buy” rating and a $70.00 target price on the stock. The consensus estimate for Greenwich LifeSciences’ current full-year earnings is ($1.29) per share. HC Wainwright also issued estimates for Greenwich LifeSciences’ Q4 2026 earnings at ($0.41) EPS, Q1 2027 earnings at ($0.37) EPS, Q2 2027 earnings at ($0.37) EPS, Q3 2027 earnings at ($0.36) EPS, Q4 2027 earnings at ($0.36) EPS and FY2027 earnings at ($1.46) EPS.

Separately, Weiss Ratings upgraded shares of Greenwich LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Greenwich LifeSciences has an average rating of “Hold” and a consensus target price of $70.00.

Read Our Latest Analysis on GLSI

Greenwich LifeSciences Price Performance

Shares of NASDAQ GLSI opened at $19.79 on Friday. Greenwich LifeSciences has a 1-year low of $7.78 and a 1-year high of $34.10. The business’s 50 day moving average is $16.78 and its two-hundred day moving average is $20.82. The stock has a market capitalization of $290.52 million, a P/E ratio of 0.00 and a beta of 1.57.

Greenwich LifeSciences (NASDAQ:GLSI – Get Free Report) last posted its earnings results on Monday, November 16th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.06).

Institutional Investors Weigh In On Greenwich LifeSciences

Hedge funds have recently made changes to their positions in the company. Deutsche Bank AG purchased a new position in shares of Greenwich LifeSciences during the second quarter valued at $126,000. Ancora Advisors LLC bought a new stake in shares of Greenwich LifeSciences in the 2nd quarter valued at about $252,000. Goldman Sachs Group Inc. lifted its position in shares of Greenwich LifeSciences by 44.4% in the 3rd quarter. Goldman Sachs Group Inc. now owns 56,793 shares of the company’s stock worth $1,025,000 after purchasing an additional 17,464 shares during the period. GSA Capital Partners LLP purchased a new stake in shares of Greenwich LifeSciences in the 2nd quarter worth approximately $458,000. Finally, Sei Investments Co. purchased a new position in Greenwich LifeSciences during the first quarter valued at approximately $627,000. 4.16% of the stock is currently owned by hedge funds and other institutional investors.

Greenwich LifeSciences News Summary

Here’s some of the latest news about GLSI:

  • Positive Sentiment: HC Wainwright raised its price target to $70 from $69 and kept its Buy rating, signaling continued confidence despite the forecast reductions. Greenwich LifeSciences stock gets price target boost from HC Wainwright
  • Neutral Sentiment: Noble Financial issued forecasts for losses of $1.49 per share in FY2026 and $2.14 in FY2027. These are new estimates rather than reported results or announced changes to its prior forecasts.
  • Negative Sentiment: HC Wainwright lowered its EPS forecasts across late 2026 and 2027. Its FY2026 estimate moved to a loss of $1.46 per share from $1.29, while its FY2027 forecast fell to a loss of $1.46 from $1.17. The wider expected losses are the clearest near-term negative in the updates.

About Greenwich LifeSciences

(Get Free Report)

Greenwich LifeSciences, Inc. is a clinical-stage biotechnology company developing immunotherapies intended to reduce the risk of breast cancer recurrence. The company’s work centers on GP2, an investigational peptide-based vaccine designed for patients with HER2/neu-positive breast cancer who have completed standard treatment. GP2 is intended to stimulate an immune response against cancer cells expressing HER2/neu and is administered with the immune-system stimulant GM-CSF. Greenwich LifeSciences is evaluating the candidate in clinical trials; it does not have an approved commercial product.

See Also

Earnings History and Estimates for Greenwich LifeSciences (NASDAQ:GLSI)

Receive News & Ratings for Greenwich LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenwich LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.